Immunic Has Enrolled The First Patient In An Investigator-sponsored Phase 2 Trial Of Its Lead Asset Vidofludimus Calcium (IMU-838) In Patients With Post Covid Syndrome
Portfolio Pulse from Benzinga Newsdesk
Immunic has enrolled the first patient in a Phase 2 trial of Vidofludimus Calcium (IMU-838) for treating post-COVID syndrome. This trial is investigator-sponsored and marks a significant step in exploring treatments for long-term COVID-19 effects.
September 04, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunic has initiated a Phase 2 trial for its drug Vidofludimus Calcium (IMU-838) targeting post-COVID syndrome. This development could potentially enhance the company's product pipeline and address a significant medical need.
The initiation of a Phase 2 trial for Vidofludimus Calcium (IMU-838) is a positive development for Immunic, as it expands their clinical pipeline and targets a significant unmet medical need. Successful trials could lead to new treatment options and potential revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90